Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

August 22, 2023

Study Completion Date

August 22, 2023

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

BDB-001 Injection

Multiple IV infusions of BDB-001 Injection diluted in sodium chloride

Trial Locations (15)

51063

The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

100005

Union Hospital Tongji Medical College Huazong University of Science and Technology, Wuhan

100034

Peking University First Hospital, Beijing

100144

Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

110000

The First Hospital of China Medical University, Shenyang

130021

The First Hospital of Jilin Universitv, Changchun

200040

Huashan Hospital of Fudan University, Shanghai

200443

Shanghai Skin Disease Hospital, Shanghai

210042

Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing

250012

Qilu Hospital of Shandong University, Jinan

410008

Xiangya Hospital, Central South University, Changsha

610041

West China Hospital of Sichuan University, Chengdu

710004

The Second Affiliated Hospital of Air Force Medical University, Xi'an

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT05093855 - Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) | Biotech Hunter | Biotech Hunter